5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Thyroid O
C-cell O
Tumors O
: O
See O
Boxed O
Warning O
( O
5.1 O
) O
. O

* O
Pancreatitis O
: O
Postmarketing O
reports O
, O
including O
fatal O
and O
non-fatal O
hemorrhagic O
or O
necrotizing O
pancreatitis O
. O

Discontinue O
promptly O
if O
pancreatitis O
is O
suspected O
. O

Do O
not O
restart O
if O
pancreatitis O
is O
confirmed O
( O
5.2 O
) O
. O

* O
Never O
share O
a O
VICTOZA O
pen O
between O
patients O
, O
even O
if O
the O
needle O
is O
changed O
( O
5.3 O
) O
. O

* O
Serious O
Hypoglycemia O
: O
When O
VICTOZA O
is O
used O
with O
an O
insulin O
secretagogue O
( O
e.g O
. O

a O
sulfonylurea O
) O
or O
insulin O
, O
consider O
lowering O
the O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia O
( O
5.4 O
) O
. O

* O
Renal O
Impairment O
: O
Postmarketing O
, O
usually O
in O
association O
with O
nausea O
, O
vomiting O
, O
diarrhea O
, O
or O
dehydration O
which O
may O
sometimes O
require O
hemodialysis O
. O

Use O
caution O
when O
initiating O
or O
escalating O
doses O
of O
VICTOZA O
in O
patients O
with O
renal O
impairment O
( O
5.5 O
) O
. O

* O
Hypersensitivity O
: O
Postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
( O
e.g. O
, O
anaphylactic O
reactions O
and O
angioedema O
) O
. O

Discontinue O
VICTOZA O
and O
promptly O
seek O
medical O
advice O
( O
5.6 O
) O
. O

* O
Acute O
Gallbladder O
Disease O
: O
If O
cholelithiasis O
or O
cholecystitis O
are O
suspected O
, O
gallbladder O
studies O
are O
indicated O
( O
5.7 O
) O
. O

5.1 O
Risk O
of O
Thyroid O
C-cell O
Tumors O
Liraglutide O
causes O
dose-dependent O
and O
treatment-duration-dependent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
( O
adenomas O
and/or O
carcinomas O
) O
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Malignant B-NonOSE_AE
thyroid I-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
carcinomas I-NonOSE_AE
were O
detected O
in O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
will O
cause O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
, O
including O
medullary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinoma I-NonOSE_AE
( I-NonOSE_AE
MTC I-NonOSE_AE
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
has O
not O
been O
determined O
. O

Cases O
of O
MTC B-OSE_Labeled_AE
in O
patients O
treated O
with O
VICTOZA O
have O
been O
reported O
in O
the O
postmarketing O
period O
; O
the O
data O
in O
these O
reports O
are O
insufficient O
to O
establish O
or O
exclude O
a O
causal O
relationship O
between O
MTC B-NonOSE_AE
and O
VICTOZA O
use O
in O
humans O
. O

VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC B-Not_AE_Candidate
or O
in O
patients O
with O
MEN B-Not_AE_Candidate
2 I-Not_AE_Candidate
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
for O
MTC B-NonOSE_AE
with O
the O
use O
of O
VICTOZA O
and O
inform O
them O
of O
symptoms O
of O
thyroid B-NonOSE_AE
tumors I-NonOSE_AE
( O
e.g O
. O

a O
mass B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
, O
dysphagia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
persistent B-NonOSE_AE
hoarseness I-NonOSE_AE
) O
. O

Routine O
monitoring O
of O
serum O
calcitonin O
or O
using O
thyroid O
ultrasound O
is O
of O
uncertain O
value O
for O
early O
detection O
of O
MTC B-NonOSE_AE
in O
patients O
treated O
with O
VICTOZA O
. O

Such O
monitoring O
may O
increase O
the O
risk O
of O
unnecessary O
procedures O
, O
due O
to O
low O
test O
specificity O
for O
serum O
calcitonin O
and O
a O
high O
background O
incidence O
of O
thyroid B-NonOSE_AE
disease I-NonOSE_AE
. O

Significantly O
elevated B-NonOSE_AE
serum I-NonOSE_AE
calcitonin I-NonOSE_AE
may O
indicate O
MTC B-NonOSE_AE
and O
patients O
with O
MTC B-NonOSE_AE
usually O
have O
calcitonin B-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
ng I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

If O
serum O
calcitonin O
is O
measured O
and O
found O
to O
be O
elevated O
, O
the O
patient O
should O
be O
further O
evaluated O
. O

Patients O
with O
thyroid B-NonOSE_AE
nodules I-NonOSE_AE
noted O
on O
physical O
examination O
or O
neck O
imaging O
should O
also O
be O
further O
evaluated O
. O

5.2 O
Pancreatitis O
Based O
on O
spontaneous O
postmarketing O
reports O
, O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal O
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
or O
necrotizing O
pancreatitis I-OSE_Labeled_AE
, O
has O
been O
observed O
in O
patients O
treated O
with O
VICTOZA O
. O

After O
initiation O
of O
VICTOZA O
, O
observe O
patients O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
( O
including O
persistent O
severe O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
sometimes O
radiating O
to O
the O
back O
and O
which O
may O
or O
may O
not O
be O
accompanied O
by O
vomiting B-NonOSE_AE
) O
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
VICTOZA O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

If O
pancreatitis B-NonOSE_AE
is O
confirmed O
, O
VICTOZA O
should O
not O
be O
restarted O
. O

In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
there O
have O
been O
13 O
cases O
of O
pancreatitis B-OSE_Labeled_AE
among O
VICTOZA-treated O
patients O
and O
1 O
case O
in O
a O
comparator O
( O
glimepiride O
) O
treated O
patient O
( O
2.7 O
vs O
. O
0.5 O
cases O
per O
1000 O
patient-years O
) O
. O

Nine O
of O
the O
13 O
cases O
with O
VICTOZA O
were O
reported O
as O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
and O
four O
were O
reported O
as O
chronic B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
. O

In O
one O
case O
in O
a O
VICTOZA-treated O
patient O
, O
pancreatitis B-OSE_Labeled_AE
, O
with I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
was O
observed O
and O
led O
to O
death O
; O
however O
clinical O
causality O
could O
not O
be O
established O
. O

Some O
patients O
had O
other O
risk O
factors O
for O
pancreatitis B-NonOSE_AE
, O
such O
as O
a O
history O
of O
cholelithiasis B-Not_AE_Candidate
or O
alcohol B-Not_AE_Candidate
abuse I-Not_AE_Candidate
. O

VICTOZA O
has O
been O
studied O
in O
a O
limited O
number O
of O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
. O

It O
is O
unknown O
if O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
higher O
risk O
for O
development O
of O
pancreatitis B-NonOSE_AE
on O
VICTOZA O
. O

5.3 O
Never O
Share O
a O
VICTOZA O
Pen O
Between O
Patients O
VICTOZA O
pens O
must O
never O
be O
shared O
between O
patients O
, O
even O
if O
the O
needle O
is O
changed O
. O

Pen-sharing O
poses O
a O
risk O
for O
transmission B-NonOSE_AE
of I-NonOSE_AE
blood I-NonOSE_AE
- I-NonOSE_AE
borne I-NonOSE_AE
pathogens I-NonOSE_AE
. O

5.4 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Patients O
receiving O
VICTOZA O
in O
combination O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
may O
have O
an O
increased O
risk O
of O
hypoglycemia B-NonOSE_AE
. O

The O
risk O
of O
hypoglycemia B-NonOSE_AE
may O
be O
lowered O
by O
a O
reduction O
in O
the O
dose O
of O
sulfonylurea O
( O
or O
other O
concomitantly O
administered O
insulin O
secretagogues O
) O
or O
insulin O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Renal B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
VICTOZA O
has O
not O
been O
found O
to O
be O
directly O
nephrotoxic B-NonOSE_AE
in O
animal O
studies O
or O
clinical O
trials O
. O

There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
worsening O
of O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
which O
may O
sometimes O
require O
hemodialysis B-NonOSE_AE
in O
VICTOZA-treated O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Some O
of O
these O
events O
were O
reported O
in O
patients O
without O
known O
underlying O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

A O
majority O
of O
the O
reported O
events O
occurred O
in O
patients O
who O
had O
experienced O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
or O
dehydration B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Some O
of O
the O
reported O
events O
occurred O
in O
patients O
receiving O
one O
or O
more O
medications O
known O
to O
affect O
renal O
function O
or O
hydration O
status O
. O

Altered B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
has O
been O
reversed O
in O
many O
of O
the O
reported O
cases O
with O
supportive O
treatment O
and O
discontinuation O
of O
potentially O
causative O
agents O
, O
including O
VICTOZA O
. O

Use O
caution O
when O
initiating O
or O
escalating O
doses O
of O
VICTOZA O
in O
patients O
with O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
) O
in O
patients O
treated O
with O
VICTOZA O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
discontinue O
VICTOZA O
; O
treat O
promptly O
per O
standard O
of O
care O
, O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
. O

Do O
not O
use O
in O
patients O
with O
a O
previous O
hypersensitivity B-Not_AE_Candidate
reaction I-Not_AE_Candidate
to O
VICTOZA O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Anaphylaxis B-NonOSE_AE
and O
angioedema B-NonOSE_AE
have O
been O
reported O
with O
other O
GLP-1 O
receptor O
agonists O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
anaphylaxis B-Not_AE_Candidate
or O
angioedema B-Not_AE_Candidate
with O
another O
GLP-receptor O
agonist O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
these O
reactions O
with O
VICTOZA O
. O

5.7 O
Acute O
Gallbladder O
Disease O
In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
3.1 O
% O
of O
Victoza-treated O
patients O
versus O
1.9 O
% O
of O
placebo-treated O
patients O
reported O
an O
acute B-OSE_Labeled_AE
event I-OSE_Labeled_AE
of I-OSE_Labeled_AE
gallbladder I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
such O
as O
cholelithiasis B-OSE_Labeled_AE
or O
cholecystitis B-OSE_Labeled_AE
. O

The O
majority O
of O
events O
required O
hospitalization O
or O
cholecystectomy O
. O

If O
cholelithiasis B-NonOSE_AE
is O
suspected O
, O
gallbladder O
studies O
and O
appropriate O
clinical O
follow-up O
are O
indicated O
. O

